Product

Single Dose Ceftazidime-Avibactam

Aliases

Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3

1 clinical trial

1 indication

Indication

Gram-negative Bacterial Infection

Clinical trial

A PHASE 2A, 2-PART, OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, SINGLE AND MULTIPLE DOSE TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF CEFTAZIDIME AND AVIBACTAM IN NEONATES AND INFANTS FROM BIRTH TO LESS THAN 3 MONTHS OF AGE WITH SUSPECTED OR CONFIRMED INFECTIONS DUE TO GRAM-NEGATIVE PATHOGENS REQUIRING INTRAVENOUS ANTIBIOTIC TREATMENT

Status: Terminated, Estimated PCD: 2022-12-30